MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals.
We have the world’s highest quality antibody libraries (MOURA Libraries) in terms of functionality and completeness, as well as highly efficient monoclonal antibody isolation technology (IMPACT). By using these, we make it possible to obtain quality monoclonal antibodies that recognize unique 3D structures or subtle structural differences of target molecules such as membrane proteins, thus contributing to new drug development opportunities in the pharmaceutical industry.
Developing pharmaceutical business for both humans and companion animals.
Prioritizing BD in the more mature human market, while entering into animal markets, which are expected to grow in the future.
|1/19/2022||(Media Feature) MabGenesis was introduced in Nikkan Kogyo Shimbun|
|1/19/2022||(Media Feature) MabGenesis was introduced in Nikkei Biotech|
|1/18/2022||(Media Feature) MabGenesis was introduced in the Nikkei|
|1/18/2022||(Press Release) Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine|
An antibody drug is a drug that utilizes an antibody that exists in a living body. By selectively binding to target molecules (antigens), antibody drugs perform various pharmacological effects.
The antibody drug market is expected to exceed 14 trillion yen in 2020, and “fully human antibodies”, which are expected to have higher efficacy and safety in the future, have become the mainstream of antibody drugs.
In the future, with the aging of companion animals (dogs and cats), it is expected that the market for complete dog/cat antibodies, which are more effective and safer for pets, will increase.